Diagnóstico de la enfermedad de von Willebrand
Resumen
La enfermedad de von Willebrand (EVW) es el trastorno hemorrágico hereditario más común, y se caracteriza por presentar disminución de la capacidad del factor von Willebrand (FVW) de unirse a las plaquetas y al colágeno de la matriz extracelular durante la hemostasia primaria, debido a defectos cuantitativos o cualitativos. La EVW se clasifica en tres fenotipos principales: el 1 y el 3 que son trastornos cuantitativos, y el 2 que se subclasifica en 2A, 2B, 2M y 2N, y refleja los trastornos cualitativos. Para su diagnóstico son necesarios varios pasos: 1) la evaluación del historial de sangrado personal y familiar del paciente, 2) detección inicial de trastornos hemorrágicos, 3) pruebas para la detección de la EVW, 4) pruebas para la tipificación de la EVW, y 5) el análisis molecular. Tanto la subclasificación de la EVW como su diagnóstico continúan planteando desafíos importantes, motivo por el cual se realiza esta revisión, de manera que los profesionales de la salud tengan una guía que los oriente al momento de tener pacientes con algún trastorno hemorrágico que amerite descartar una EVW e implementar un tratamiento adecuado.
Descargas
Referencias bibliográficas
Weyand AC, Flood VH. von Willebrand disease: Current status of diagnosis and management. Hematol Oncol Clin North Am 2021;35:1085-1101. https://doi.org/10.1016/j.hoc.2021.07.004.
Tosetto A, Castaman G. How I treat type 2 variant forms of von Willebrand disease. Blood 2015;125:907-914. https://doi.org/10.1182/blood-2014-08-551960.
Baronciani L, Peyvandi F. How we make an accurate diagnosis of von Willebrand disease. Thromb Res 2020;196:579-589. https://doi.org/10.1016/j.thromres.2019.07.010.
Kreuz W. von Willebrand's disease: from discovery to therapy - milestones in the last 25 years. Haemophilia 2008;14:S1-2. https://doi.org/10.1111/j.1365-2516.2008.01846.x.
Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-694. https://doi.org/10.1056/NEJMra040403.
Fogarty H, Doherty D, O'Donnell JS. New developments in von Willebrand disease. Br J Haematol 2020;191:329-339. https://doi.org/10.1111/bjh.16681.
Sladič M, Verdenik I, Smrkolj Š. The effect of von Willebrand Disease on pregnancy, delivery, and postpartum period: A retrospective observational study. Medicina (Kaunas) 2022;58. https://doi.org/10.3390/medicina58060774.
Millar C. Why and how do we classify von Willebrand disease? Haemophilia 2015;21:407-410. https://doi.org/https://doi.org/10.1111/hae.12725.
Budde U. Diagnosis of von Willebrand disease subtypes: implications for treatment. Haemophilia 2008;14 Suppl 5:27-38. https://doi.org/10.1111/j.1365-2516.2008.01849.x.
James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021;5:280-300. https://doi.org/10.1182/bloodadvances.2020003265.
World Federation of Hemophilia (WFH). Data collection. Report on the WFH Annual Global Survey 2020. Québec, Cánada: WFH; 2020. Acceso 28 de octubre de 2022. Disponible en https://wfh.org/data-collection/.
Al-Rahal NK. Inherited bleeding disorders in iraq and consanguineous marriage. Int J Hematol Oncol Stem Cell Res 2018;12:273-281.
Wang X, Tang N, Lu Y, Hu Q, Li D. Two cases of von Willebrand disease type 3 in consanguineous Chinese families. Mol Genet Genomic Med 2020;8:e1075. https://doi.org/10.1002/mgg3.1075.
Borhany M, Pahore Z, Ul Qadr Z, Rehan M, Naz A, Khan A, et al. Bleeding disorders in the tribe: result of consanguineous in breeding. Orphanet J Rare Dis 2010;5:23. https://doi.org/10.1186/1750-1172-5-23.
Stufano F, Baronciani L, Peyvandi F. Diagnóstico de la enfermedad de von Willebrand: Caracterización fenotípica. Québec, Canadá: Federación Mundial de Hemofilia (FMH); 2017. Acceso 31 de octubre de 2022. Disponible en https://elearning.wfh.org/es/resource/diagnostico-de-la-enfermedad-de- von-willebrand-caracterizacion-fenotipica/.
Sadler B, Castaman G, O'Donnell JS. von Willebrand disease and von Willebrand factor. Haemophilia 2022;28 Suppl 4:S11-17. https://doi.org/10.1111/hae.14547.
Swami A, Kaur V. von Willebrand disease: A concise review and update for the practicing physician. Clin Appl Thromb Hemost 2017;23:900-910. https://doi.org/10.1177/1076029616675969.
Ledford-Kraemer MR. Analysis of von Willebrand factor structure by multimer analysis. Am J Hematol 2010;85:510-514. https://doi.org/10.1002/ajh.21739.
Zeng J, Shu Z, Liang Q, Zhang J, Wu W, Wang X, et al. Structural basis of von Willebrand factor multimerization and tubular storage. Blood 2022;139:3314-3324. https://doi.org/10.1182/blood.2021014729.
Laffan M, Sathar J, Johnsen JM. von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis. Haemophilia 2021;27:S66-74. https://doi.org/10.1111/hae.14050.
Yee A, Kretz CA. von Willebrand factor: form for function. Semin Thromb Hemost 2014;40:17-27. https://doi.org/10.1055/s-0033-1363155.
Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014;25:206-216. https://doi.org/10.1097/mbc.0000000000000065.
Leebeek FW, Eikenboom JC. von Willebrand's disease. N Engl J Med 2016;375:2067-2080. https://doi.org/10.1056/NEJMra1601561.
Kovacevic KD, Grafeneder J, Schörgenhofer C, Gelbenegger G, Gager G, Firbas C, et al. The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial. Haematologica 2022;107:2121-2132. https://doi.org/10.3324/haematol.2021.279948.
Sharma R, Flood VH. Advances in the diagnosis and treatment of von Willebrand disease. Blood 2017;130:2386-2391. https://doi.org/10.1182/blood-2017-05-782029.
National Heart, Lung, and Blood Institute (NHLBI). The diagnosis, evaluation and management of von Willebrand Disease (full report). Bethesda, Estados Unidos,: NHLBI; 2007. Acceso 31 de octubre de 2022. Disponible en https://www.nhlbi.nih.gov/resources/diagnosis-evaluation-and-management- von-willebrand-disease-full-report.
Goodeve A. Genetics of type 1 von Willebrand disease. Curr Opin Hematol 2007;14:444-449. https://doi.org/10.1097/MOH.0b013e32826f4b41.
Soto AV, Morales GM, Verdugo LP. Empleo del DDAVP en el manejo de la enfermedad de von Willebrand. Rev Chil Pediatr 2005;76:193-197.
Ng CJ, Di Paola J. von Willebrand Disease: Diagnostic strategies and treatment options. Pediatr Clin North Am 2018;65:527-541. https://doi.org/10.1016/j.pcl.2018.02.004.
Kruse-Jarres R, Johnsen JM. How I treat type 2B von Willebrand disease. Blood 2018;131:1292-1300. https://doi.org/10.1182/blood-2017-06-742692.
Doruelo AL, Haberichter SL, Christopherson PA, Boggio LN, Gupta S, Lentz SR, et al. Clinical and laboratory phenotype variability in type 2M von Willebrand disease. J Thromb Haemost 2017;15:1559-1566. https://doi.org/10.1111/jth.13742.
Seidizadeh O, Peyvandi F, Mannucci PM. von Willebrand disease type 2N: An update. J Thromb Haemost 2021;19:909-916. https://doi.org/10.1111/jth.15247.
Castaman G. How I treat von Willebrand disease. Thromb Res 2020;196:618-625. https://doi.org/10.1016/j.thromres.2020.07.051.
Makris M, Hermans C. The 2021 von Willebrand disease guidelines: Clarity and controversy. Haemophilia 2022;28:1-3. https://doi.org/10.1111/hae.14465.
Lavin M, Christopherson P, Grabell J, Abshire T, Flood V, Haberichter SL, et al. Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score. J Thromb Haemost 2022;20:2246-2254. https://doi.org/10.1111/jth.15807.
Laffan MA, Lester W, O'Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014;167:453-465. https://doi.org/10.1111/bjh.13064.
Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171-232. https://doi.org/10.1111/j.1365-2516.2007.01643.x.
Kalot MA, Husainat N, El Alayli A, Abughanimeh O, Diab O, Tayiem S, et al. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Adv 2022;6:62-71. https://doi.org/10.1182/bloodadvances.2021005430.
Castaman G, Linari S. Diagnosis and treatment of von Willebrand disease and rare bleeding disorders. J Clin Med 2017;6:45. https://doi.org/10.3390/jcm6040045.
Bowman ML, James PD. Controversies in the diagnosis of type 1 von Willebrand disease. Int J Lab Hematol 2017;39 Suppl 1:61-68. https://doi.org/10.1111/ijlh.12653.
Seidizadeh O, Baronciani L, Pagliari MT, Cozzi G, Colpani P, Cairo A, et al. Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2. Blood Adv 2022;6:4031-4040. https://doi.org/10.1182/bloodadvances.2022007216.
Practical-Haemostasis.com. von Willebrand factor [VWF]: Introduction. Cambridge, UK: Sang Medicine Ltd; 2022. Acceso 31 de octubre de 2022. Disponible en https://practical-haemostasis.com/Factor%20Assays/vwf/vwf_assays_introduction.html.
Woods AI, Rossetti LC, Paiva J, De Brasi CD, Romero ML, Casinelli MM, et al. Type 2N von Willebrand disease: Is it always a recessive trait? Thromb Res 2021;198:49-51. https://doi.org/10.1016/j.thromres.2020.11.029.
Gritsch H, Stimpfl M, Turecek PL. von Willebrand factor multimer analysis by low resolution SDS-agarose gel electrophoresis. Bio Protoc 2022;12:e4495. https://doi.org/10.21769/BioProtoc.4495.
Saadalla A, Seheult J, Pruthi RK, Chen D. von Willebrand factor multimer analysis and classification: A comprehensive review and updates. Semin Thromb Hemost 2022. [Epub ahead of print] Sep 29 de 2022. https://doi.org/10.1055/s-0042-1757183.
Favaloro EJ, Pasalic L, Curnow J. Type 2M and type 2A von Willebrand disease: Similar but different. Semin Thromb Hemost 2016;42:483-497. https://doi.org/10.1055/s-0036-1579641.
Hermans C, Batlle J. Autosomal dominant von Willebrand disease type 2M. Acta Haematol 2009;121:139-144. https://doi.org/10.1159/000214854.
Frontroth JP, Favaloro EJ. Ristocetin-induced platelet aggregation (RIPA) and RIPA mixing studies. Methods Mol Biol 2017;1646:473-494. https://doi.org/10.1007/978-1-4939-7196-1_35.
Fels S, Boeckelmann D, Glonnegger H, Büchsel M, Zieger B. Novel Likely Pathogenic Variant in the A3 Domain of von Willebrand Factor Leading to a Collagen-Binding Defect. Hamostaseologie 2022. https://doi.org/10.1055/a-1701-2181.
Goodeve A. Diagnosing von Willebrand disease: genetic analysis. Hematology Am Soc Hematol Educ Program 2016;2016:678-682. https://doi.org/10.1182/asheducation-2016.1.678.
Flood VH, Garcia J, Haberichter SL. The role of genetics in the pathogenesis and diagnosis of type 1 von Willebrand disease. Curr Opin Hematol 2019;26:331-335. https://doi.org/10.1097/moh.0000000000000524.
Adil SN, Qureshi A. von Willebrand disease-An under diagnosed entity. J Pak Med Assoc 2008;58:157-158.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
